Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT05674994
PHASE3

Glucocorticoids Versus Placebo for the Treatment of Acute Exacerbation of Idiopathic Pulmonary Fibrosis

Sponsor: Fondation Hôpital Saint-Joseph

View on ClinicalTrials.gov

Summary

Acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF) is associated with a poor prognosis, with a 3-month mortality rate of over 50%. To date, no treatment has been proven to be effective in AI-FPI. The interest of glucocorticoids is controversial and needs to be confirmed. This confirmation is mandatory to validate the improvement of the prognosis of EA-IPF under this treatment but also to search for unsuspected deleterious effects as it has been shown with immunosuppressants in stable idiopathic pulmonary fibrosis.

Official title: Glucocorticoids Versus Placebo for the Treatment of Acute Exacerbation of Idiopathic Pulmonary Fibrosis: a Randomized Controlled Trial

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

110

Start Date

2023-10-26

Completion Date

2026-12-31

Last Updated

2026-03-02

Healthy Volunteers

No

Interventions

DRUG

Methylprednisone/Prednisone

Patients will be enrolled during their hospitalization in pneumology department, as part of current practice, within 7 days of the screening visit. The investigator will perform randomization by connecting to the eCRF, randomization be stratified for the severity of IPF and the treatment with antifibrotic therapy (Nintedanib or Pirfenidone) (yes/no). If patient is randomized in Glucocorticoids Group: * Day 1, 2 and 3: Intravenous Methylprednisolone 10 mg/kg/d (without exceeding 1000 mg/d). Vials of injectable solution of methylprednisolone® are diluted in 100 ml of NaCl 0.9% or G5%. Perfusion duration is between 20 to 30 minutes. * From day 4 to Day 30: Oral Prednisone slow tappering * 1 mg/kg/d for 7 days * 0.5 mg/kg/d for 7 days * 0.25 mg/kg/d for 7 days, * 10 mg/d until Day 30. For 10mg/kg, 1 mg/kg, 0.5 mg/kg, 0.25 mg/kg; rounding to 5 decimal lower if decimal ≤ 7 and the top ten if decimal ≥ 8.

OTHER

Placebo

Patients will be enrolled during their hospitalization in pneumology department, as part of current practice, within 7 days of the screening visit. The investigator will perform randomization by connecting to the eCRF, randomization be stratified for the severity of IPF and the treatment with antifibrotic therapy (Nintedanib or Pirfenidone) (yes/no). If patient is randomized in Placebo Group: Day 1, 2 and 3: Intravenous Methylprednisolone-Placebo From Day 4 to Day 30: Oral Prednisone-Placebo The Methylprednisolone-Placebo corresponds to 100 ml of NaCl 0.9 % or G5%. Perfusion duration is between 20 to 30 minutes. For the Prednisone-Placebo, the placebo was an oral solution formulated with a bittering agent (pharmaceutical excipient). Specifically, in place of prednisone, sucrose octaacetate (defined as a GRAS-'Generally Recognized as Safe' excipient by the EMA) was used at 5 mg/mL.

Locations (29)

CHU ANgers

Angers, France

CHU de Besancon

Besançon, France

Hôpital Avicenne

Bobigny, France

CHU BOrdeaux

Bordeaux, France

CHU Caen

Caen, France

CHU Clermont-Ferrand

Clermont-Ferrand, France

CHIC

Créteil, France

CHU de Dijon

Dijon, France

CHU Grenoble

Grenoble, France

CHRU Lille

Lille, France

Hospices Civils de Lyon

Lyon, France

Hôpital Nord

Marseille, France

CHU de Montpellier

Montpellier, France

CHU Nancy

Nancy, France

CHU de Nantes

Nantes, France

CHU Nice

Nice, France

Hôpital Paris Saint-Joseph

Paris, France

Hôpital Bichat

Paris, France

Hôpital Européen Georges Pompidou

Paris, France

Hôpital FOCH

Paris, France

Hôpital Kremiln Bicetre

Paris, France

Hôpital Saint-Louis

Paris, France

Hôpital Tenon

Paris, France

CHU Reims

Reims, France

CHU Rennes

Rennes, France

CHU Rouen

Rouen, France

CHU Strasbourg

Strasbourg, France

CHU Toulouse

Toulouse, France

CHU Tours

Tours, France